Download PDF
Nuklearmedizin 2017; 56(03): N22-N23
DOI: 10.3413/Nukmed-0868-16-12
Case report
Schattauer GmbH

Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue

Kathrin Kahnert
1   Department of Internal Medicine V, Thoracic Oncology Centre Munich, University of Munich, Comprehensive Pneumology Centre, Munich, Germany
,
Diego Kauffmann-Guerrero
1   Department of Internal Medicine V, Thoracic Oncology Centre Munich, University of Munich, Comprehensive Pneumology Centre, Munich, Germany
,
Amanda Tufman
1   Department of Internal Medicine V, Thoracic Oncology Centre Munich, University of Munich, Comprehensive Pneumology Centre, Munich, Germany
,
Astrid Borgmeier
1   Department of Internal Medicine V, Thoracic Oncology Centre Munich, University of Munich, Comprehensive Pneumology Centre, Munich, Germany
,
Rudolf M. Huber
2   Department of Internal Medicine V, Thoracic Oncology Centre Munich, member of the German Center for Lung Research (DZL – CPC-M), University of Munich, Comprehensive Pneumology Centre, Munich, Germany
,
Frank Berger
3   Department of Clinical Radiology, University of Munich, Munich, Germany
› Author Affiliations
Further Information

Publication History

received: 18 December 2016

accepted in revised form: 03 April 2017

Publication Date:
02 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumours. Ann Oncol 2000; 11 (10) 1335-1341.
    CrossrefPubMedGoogle Scholar
  • 2 Aldarouish M, Wang C. Trends and advances in tumour immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 2016; 35 (01) 157.
    CrossrefPubMedGoogle Scholar
  • 3 Burger IA, Husmann L, Hany TF. et al. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin Nucl Med 2011; 36 (10) 848-853.
    CrossrefPubMedGoogle Scholar
  • 4 Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid tumours. J Clin Oncol 2015; 33 (31) 3541-3543.
    CrossrefPubMedGoogle Scholar
  • 5 Georgoulias V, Douillard JY, Khayat D. et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-smallcell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 2013; 14 (04) 461-465.
    CrossrefPubMedGoogle Scholar
  • 6 Hoos A, Parmiani G, Hege K. et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30 (01) 1-15.
    CrossrefPubMedGoogle Scholar
  • 7 Liang F, Lore K. Local innate immune responses in the vaccine adjuvant-injected muscle. Clin Transl Immunology 2016; 5 (04) e74.
    PubMedGoogle Scholar
  • 8 Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014; 3: 135-150.
    PubMedGoogle Scholar
  • 9 Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10 (06) 673-679.
    CrossrefPubMedGoogle Scholar